KeyBanc reiterates Overweight on Elanco Animal Health stock

Published on 10/02/2026 at 20:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

KeyBanc kept its Overweight rating and USD 30.00 target. Elanco Animal Health stock costs EUR 19.56 on October 2, 2026, plus 0.20 percent versus EUR 19.52.

ELAN, US28414H1032, Illustration mit AI erstellt.

Elanco Animal Health (US28414H1032) was backed by a reiterated Overweight rating and a USD 30.00 price target from KeyBanc on September 30, 2026, according to Investing.com. The rating keeps product adoption and veterinary demand at the center of the stock case.

KeyBanc sees parasiticide traction

KeyBanc based its view partly on a mid-September survey of 50 U.S. veterinary clinics. According to Investing.com, 64.00 percent of the clinics said they were prescribing more broad-spectrum parasiticides than in the prior year. Elanco's Quattro and Zenrelia products were identified as adoption drivers in the same September 30, 2026 report.

The survey also separates product categories. Broad-spectrum parasiticides showed stronger demand than dermatology products, giving the company a measurable commercial signal behind the reiterated rating.

Second-quarter figures beat estimates

Elanco reported adjusted earnings per share of USD 0.34 in the second quarter of 2026 versus a USD 0.27 consensus estimate. Revenue reached USD 1.37 billion, compared with USD 1.31 billion expected, and increased 10.20 percent from the same quarter a year earlier, according to MarketBeat.

The earnings comparison matters because the USD 0.07 adjusted earnings-per-share surplus and USD 0.06 billion revenue gap versus consensus offer a concrete test of the product-led growth narrative. MarketBeat also reported full-year 2026 adjusted earnings-per-share guidance of USD 1.10 to USD 1.16.

Next report date is November 6

Elanco's investor-relations calendar schedules its third-quarter 2026 earnings release for November 6, 2026, with the call at 8:00 a.m. EST, according to Elanco Animal Health. The date gives the market a defined checkpoint for testing the USD 1.10 to USD 1.16 full-year adjusted earnings-per-share range.

MarketBeat said eight of 12 analysts rated the stock a buy, one rated it a strong buy, and the average 12-month target was USD 29.70 on September 27, 2026. That consensus target sits above the KeyBanc target, showing that the analyst range remains broad even after the recent reiteration.

Lang & Schwarz quote on October 2

Elanco Animal Health stock was trading at EUR 19.56 at Lang & Schwarz on October 2, 2026, at 8:08 p.m. CEST, plus 0.20 percent versus the prior close of EUR 19.52 on October 1, 2026. On the NYSE, ELAN was at USD 22.01 at 2:09 p.m. EDT on October 2, 2026, while the 52-week range was USD 19.40 to USD 27.98 and market capitalization was USD 11.0 billion.